FIELD: pharmacology.
SUBSTANCE: invention relates to novel deuterated diaminopyrimidines of the general formula
(I) and their pharmaceutically acceptable salts. In the general formula (I) R1a, R1b, R1c, R2a, R2b, R2c, R3, R4, R6, R7, R9, R10, R11, R12, R13a, R13b, R13c, R14a, R14b, R14c, R15a, R15b, R15c, R16, R17a, R17b, R18a, R18b, R19a, R19b, R20a and R20b independently hydrogen or deuterium; R5 is hydrogen, deuterium or halogen, R8 Represents a halogen; Provided that at least four of R1a, R1b, R1c, R2a, R2b, R2c, R3, R12, R13a, R13b, R13c, R14a, R14b, R14c, R19a, R19b, R20a or R20b are deuterium. The invention also relates to a process for the preparation of compounds of general formula (I) by reacting compound 
A6 with compound 
XV and to intermediates A6 and XV. In this case, in compound A6 R10, R11, R12, R13a, R13b, R13c, R14a, R14b, R14c, R15a, R15b, R15c, R16, R17a, R17b, R18a, R18b, R19a, R19b, R20a or R20b are independently selected from deuterium or hydrogen and at least one of them is deuterium; In compound XV R1a, R1b, R1c, R2a, R2b, R2c, R3, R4, R6, R7, R9 are independently selected from hydrogen or deuterium and at least one of them is deuterium; and R5 is hydrogen, deuterium or halogen; and R8 represents a halogen; X2 is selected from F, Cl, Br, I.
EFFECT: compounds have ALK protein kinase inhibitory properties and can be used to treat or prevent cancer, impair cell proliferation, cardiovascular diseases, inflammation, infection, autoimmune diseases, organ transplantation, viral diseases, cardiovascular diseases or metabolic diseases.
18 cl, 4 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| CHEMICAL METHOD OF PRODUCING PYRIMIDINE DERIVATIVES AND INTERMEDIATE COMPOUNDS THEREOF | 2015 |
|
RU2703300C2 |
| DERIVATIVE OF PYRIMIDINE AND A FIVE-MEMBERED NITROGEN-CONTAINING HETEROCYCLE, METHOD FOR PRODUCTION AND MEDICAL APPLICATIONS THEREOF | 2019 |
|
RU2775229C1 |
| SUBSTITUTED N2-(4-AMINO-2-METHOXYPHENYL)-N4-[2-(DIMETHYLPHOSPHORYL)-PHENYL]-5-CHLORO-PYRIMIDINE-2,4-DIAMINES AS MODULATORS OF ALK AND EGFR, APPLICABLE FOR TREATING CANCER | 2015 |
|
RU2607371C1 |
| CRYSTAL FORMS 5-CHLORO-N2 - (2-ISOPROPOXY-5-METHYL-4-PIPERIDINE-4-YL-PHENYL) - N 4 - [2-(PROPANE-2-SULFONYL)- PHENYL] - PYRIMIDINE-2,4-DIAMINE | 2011 |
|
RU2746159C2 |
| DERIVATIVES OF 2,4-SUBSTITUTED PHENYLENE-1,5-DIAMINE AND THEIR USES, PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS OBTAINED FROM THEM | 2015 |
|
RU2649001C1 |
| INHIBITOR COMPOUNDS | 2013 |
|
RU2673079C2 |
| IMIDAZOPYRAZINES | 2012 |
|
RU2600327C2 |
| EGFR INHIBITOR COMPOUNDS | 2017 |
|
RU2751341C2 |
| ALK KINASE INHIBITORS | 2013 |
|
RU2675850C2 |
| COMPOUNDS | 2016 |
|
RU2725616C2 |
